Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy

Urology

Volumn 76, Issue 2, 2010, Pages 436-441

  Tubaro, Andrea ^a   De Nunzio, Cosimo ^a   Mariani, Simone ^a   Trucchi, Alberto ^a   Miano, Roberto ^a   Vicentini, Carlo ^a   Miano, Lucio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

AGED; ARTICLE; CANCER INCIDENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFECT; HUMAN; HUMAN TISSUE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; SENSITIVITY AND SPECIFICITY; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATISM; SULFONAMIDES;

EID: 77955713925     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.12.083     Document Type: Article

References (30)

1. M.K. Brawer, M.P. Chetner, and J. Beaie Screening for prostatic carcinoma with prostate specific antigen J Urol 147 1992 841 845
2. W.J. Catalona, D.S. Smith, and T.L. Ratliff Detection of organ confined prostate cancer is increased through prostate-specific antigen-based screening JAMA 270 1993 948 954
3. A. Heidenreich, G. Aus, and M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68 80
4. AUA Guidelines Committee AUA guideline on management of benign prostatic hyperplasia Chapter 1: diagnosis and treatment recommendations J Urol 170 2003 530 542
5. M.G. Lucas, T.P. Stephenson, and V. Nargund Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia BJU Int 95 2005 354 357
6. P.F. Austin, Y.L. Homsy, and J.L. Masel Alpha-adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction J Urol 162 1999 1064 1067
7. S.A. Kaplan, J.D. McConnell, and C.G. Roehrborn Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater J Urol 175 2006 217 220
8. C.G. Roehrborn, J.E. Oesterling, and P.J. Olson Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin Urology 50 1997 556 561
9. C.R. Chapple, J.J. Wyndaele, J. Nordling European Tamsulosin Study Group The first prostate-selective alpha 1A-adrenoceptor antagonist: a meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH) Eur Urol 29 1996 155 157
10. C.M. Benning, and N. Kyprianou Quinazoline derived α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1-adrenoceptor- independent action Cancer Res 62 2002 597 602
11. A. Trucchi, C. De Nunzio, and S. Mariani A local anesthesia reduces pain associated with transrectal prostatic biopsy: a prospective randomized study Urol Int 74 2005 209 214
12. R.B. Nadler, P.A. Humphrey, and D.S. Smith Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels J Urol 154 1995 407 413
13. P. Ulleryd, B. Zackrisson, and G. Aus Prostatic involvement in men with febrile urinary tract infections measured by serum specific antigen and transrectal ultrasound BJU Int 84 1999 470 474
14. J. Irani, P. Levillain, and J.M. Goujon Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value J Urol 157 1997 1301 1303
15. Y. Hasui, K. Marutsuka, and Y. Asada Relationship between serum PSA and histological prostatitis in patients with benign prostate hyperplasia Prostate 25 1994 91 95
16. P.H. Schatteman, L. Hoekx, and J.J. Wyndaele Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density Eur Urol 37 2000 404 412
17. B.H. Gumus, N. Nese, and M.I. Gunduz Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens Int Urol Nephrol 36 2004 549 553
18. J. Morote, M. Lopez, and G. Encambo Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen Eur Urol 37 2000 537 540 (Pubitemid 30189821)
19. D. Minardi, A.B. Galosi, and A. Recchioni Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients Urol Int 67 2001 272 282
20. I. Stancik, W. Luftenegger, and M. Klimpfinger Effect of NIH-IV prostatitis on free and free-to-total PSA Eur Urol 46 2004 760 764
21. V. Scattoni, M. Raber, and F. Montorsi Percentage of free serum prostate-specific antigen and histological findings in patients undergoing open prostatectomy for benign prostatic hyperplasia Eur Urol 36 1999 621 630
22. C.B. Bozeman, B.S. Carver, and J.A. Eastham Treatment of chronic prostatitis lowers serum prostate specific antigen J Urol 16 2002 1723 1726
23. G. Karazanashvili, and L. Managadze Prostate-specific antigen (PSA) value change after antibacterial therapy of prostate inflammation, as a diagnostic method for prostate cancer screening in cases of PSA value within 4-10 ng/ml and non suspicious results of digital rectal examination Eur Urol 39 2001 538 543
24. O. Kaygisiz, O. Ugurlu, and M. Kosan Effects of antibacterial therapy on PSA change in the presence and absence of prostatic inflammation in patients with PSA level between 4 and 10 ng/ml Prostate Cancer Prostatic Dis 9 2006 253 258
25. H. Erol, N. Beder, and T. Caliskan Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA level discriminate between benign and malign prostatic pathologies? Urol Int 76 2006 20 26
26. M.A. Babul, W. Wazzan, and A. Hijaz The effect of antibiotics on elevated serum prostate specific antigen in patients with urinary symptoms and negative digital rectal examination: a pilot study J Med Liban 50 2002 23 25
27. N. Kyprianou, J. Chon, and C.M. Benning Effects of α1-adrenoceptor antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease Prostate Suppl 9 2000 42 46
28. N. Kyprianou Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance J Urol 169 2003 1520 1525
29. P. Narayan Tamsulosin: the United States trials Geriatrics 53 1998 29 32
30. T. Hanai, S. Matsumoto, and S. Shouji The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA levela study for comparison of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) and prostate cancer Hinyokika Kiyo 55 2009 187 191